Pharmacodynamics<unk>  is a progestogen, and hence is an agonist of the progesterone receptor (PR). It is a highly potent progestogen, showing 50 times the potency of progesterone in the Clauberg test. The ovulation-inbhiting dosage of<unk>  is 2.5 mg/day, while the endometrial transformation dosage is 100 mg per cycle. The medication is devoid of androgenic activity, and instead has some antiandrogenic activity.<unk>  has low affinity for the glucocorticoid receptor. In a particular bioassay, both<unk>  and progesterone showed antiglucocorticoid rather than glucocorticoid activity. The major metabolite of<unk> , a 21-hydroxylated metabolite, is a moderately potent progestogen (4 times the potency of progesterone) and a weak mineralocorticoid (2% of the potency of deoxycorticosterone). Relative affinities (%) of<unk>  Compound<unk>  230 1 0 5 1–2 ? ? Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the , testosterone for the , for the , for the , aldosterone for the , for , and cortisol for . Sources: Pharmacokinetics<unk>  has good bioavailability. The initial volume of distribution of<unk>  is 31 L.<unk>  is metabolized by hydroxylation at the C21, C1, C2, and C11 positions, which is eventually followed by A-ring aromatization after 1,2-dehydration. The major metabolite of<unk>  is a 21-hydroxy derivative. The metabolic clearance rate of<unk>  is 20 L/h. Its biological half-lives are 2.39 and 0.24 hours with intravenous injection.<unk>  and/or its metabolites are excreted, at least in part, in urine.
Demegestone
Trimegestone
Trengestone
Diatragacanth
Prayer callus
Cradle cap
Oak wilt
Facies 